Congestion is the permanent mechanism driving disease progression in patients with acute
heart failure (AHF) and also is an important treatment target. However, distinguishing …

All patients with heart diseases should undergo risk stratification to predict those who are at
high risk for short-and long-term adverse outcomes. Carbohydrate antigen 125 (CA125) is a …

Background Elevated plasma carbohydrate antigen-125 (CA-125) levels are strongly
associated with new-onset atrial fibrillation (AF) and heart failure, but the relationship …

Heart failure (HF) is the end result of many different cardiac and non-cardiac abnormalities
leading to a complex clinical entity. In this view, the use of biomarkers in HF should be …

Objective Plasma cancer antigen (CA)-125 is a tumour marker recently shown to be
associated with systolic heart failure and new-onset atrial fibrillation (AF) after myocardial …

Background Cancer antigen-125 (Ca-125) is traditionally recognised as a tumour marker
and its role in cardiovascular diseases has been studied only in recent years. Whether Ca …

(1) Background: Cancer antigen 125 (CA125) is a glycoprotein that is expressed by tissue
derived from coelomic epithelium in the pleura, peritoneum, pericardium. It has been shown …

In risk-stratifying patients with atrial fibrillation (AF), physicians rely heavily on clinical
parameters that provide risk scores and determine treatment strategies. There has been …

Background An accurate estimation of the duration of atrial fibrillation is critical for its safe
management. Recent studies suggested that copeptin, carbohydrate antigen-125, galectin-3 …

Heart failure affects nearly 26 million people worldwide. Patients with heart failure are
frequently affected with atrial fibrillation, and the interrelation between these pathologies is …